Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25397835 | 0.79 | CYP19A1 (0.53) | CYP19A1CYP3A4CYP2C19 | |
| SCHEMBL28372101 | 0.78 | CYP2C19 (0.30) | CYP2C19 | |
| SCHEMBL5702559 | 0.78 | CYP19A1 (0.56) | CYP19A1CYP2C19 | |
| SCHEMBL9912807 | 0.78 | CYP19A1 (0.51) | CYP19A1CYP2C19 | |
| SCHEMBL5702555 | 0.78 | CYP19A1 (0.51) | CYP19A1CYP2C19 | |
| SCHEMBL119668 | 0.78 | CYP19A1 (0.51) | CYP19A1CYP2C19 | |
| SCHEMBL10609695 | 0.76 | ALDH1A1 (0.47) | CYP19A1CYP3A4MEN1CYP1A2CYP2C19 | |
| SCHEMBL8386198 | 0.76 | CYP19A1 (0.50) | CYP19A1CYP2C19 | |
| SCHEMBL2065251 | 0.76 | CYP19A1 (0.50) | CYP19A1CYP1A2CYP2C19 | |
| SCHEMBL18744849 | 0.76 | CYP19A1 (0.50) | CYP19A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093536-A1 | Target protein of antidiabetic and novel antidiabetic insuful corresponding thereto | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1698696-A1 | TARGET PROTEIN OF ANTIDIABETIC AGENT AND NOVEL ANTIDIABETIC AGENT INSUFUL CORRESPONDING THERETO | Reverse Proteomics Research Institute Co., Ltd (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093536-A1 | Target protein of antidiabetic and novel antidiabetic insuful corresponding thereto | IGFBP4, IGF2BP1, INSRR | CYP19A1 4170/4885CYP3A4 4154/4885MEN1 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.